ASX Filings

Ceasing to be a substantial holder for ANP

May 11, 2018

Opthea Doses wAMD Patients in Europe and Israel

March 27, 2018

Opthea Half Year Report and Accounts

February 19, 2018

Appendix 3B

January 12, 2018

Opthea Corporate Presentation - January 2018

January 8, 2018

Opthea Receives A$2.7m R&D Tax Incentive

January 8, 2018

Opthea Initiates OPT-302 Diabetic Macular Edema Trial

January 3, 2018

Change in substantial holding

December 22, 2017

Change in substantial holding (Full copy)

December 19, 2017

Opthea Doses First Patient in OPT-302 wAMD Ph2b trial

December 19, 2017